Evidence map›Paper›PMID 36794157›Full record

ReviewInternational journal of medical sciences2023

Mechanism of CD38 via NAD

Min Dong, Shuo Wang, Zuowei Pei

Open access · goldAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in International journal of medical sciences, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed, 1 pooled it
1.8field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 1 synthesis or guideline pooled it, 7 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 3 institutions in 1 country.

Min DongDepartment of Cardiology, Beijing Hospital, National Center of Gerontology, Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, Beijing, China.
Shuo WangDepartment of Internal Medicine, The Affiliated Zhong Shan Hospital of Dalian University, Dalian, China.
Zuowei PeiDepartment of Cardiology, Central Hospital of Dalian University of Technology, Dalian, China.
Affiliated Zhongshan Hospital of Dalian University · CNChinese Academy of Medical Sciences & Peking Union Medical College · CNDalian University of Technology · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Non-alcoholic fatty liver disease (NAFLD) is the most common chronic liver disease globally, and it can proceed to cirrhosis and hepatocellular carcinoma, as well as cardiovascular disease, chronic renal disease, and other complications, resulting in a massive economic burden. At the moment, nicotinamide adenine dinucleotide (NAD

Indexed as

ADP-ribosyl Cyclase 1Insulin ResistanceMembrane GlycoproteinsNon-alcoholic Fatty Liver DiseaseAnimalsHumansLipidsLiverMiceNADADP-ribosyl Cyclase 1CD38 protein, humanLipidsMembrane GlycoproteinsNADCD38Lipid accumulation.Macrophage-1 Insulin resistanceNAD+Non-alcoholic fatty liver disease

Identifiers

PMID36794157
PMCPMC9925988
OpenAlexW4318831169

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.